This site is intended for US healthcare professionals.

Find a TGCT Center
Location:ZIP Code is mandatory
100 Miles

200 Miles

300 Miles

400 Miles

500 Miles

1000 Miles
Filter:At least one option is mandatory

TURALIO REMS-Certified Prescriber

Sarcoma Treatment Center
Request a Rep
Request a Rep

TURALIO^® (pexidartinib) is available to prescribe! Complete the form below to speak with a sales representative about TURALIO.

*Required information.

Medical Oncologist

Orthopedic Oncologist

Orthopedic Surgeon

Hematologist-Oncologist

Rheumatologist

PCP

Other

Please choose an option.

Please enter your first name. Please enter valid characters in first name Please enter valid first name

Please enter your last name. Please enter valid characters in last name Please enter valid last name

Alabama

Alaska

American Samoa

Arizona

Arkansas

California

Colorado

Connecticut

Delaware

District of Columbia

Federated States of Micronesia

Florida

Georgia

Guam

Hawaii

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maine

Marshall Islands

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Montana

Nebraska

Nevada

New Hampshire

New Jersey

New Mexico

New York

North Carolina

North Dakota

Northern Mariana Islands

Ohio

Oklahoma

Oregon

Palau

Pennsylvania

Puerto Rico

Rhode Island

South Carolina

South Dakota

Tennessee

Texas

Utah

Vermont

Virgin Islands

Virginia

Washington

West Virginia

Wisconsin

Wyoming

Please enter a valid ZIP Code.

Please enter a valid email address.

Learn more about TURALIO

Learn more about TURALIO Access

Learn more about TURALIO Patient Support & Savings

Learn more about TURALIO REMS Certification

Other

Please choose an option.

True

reCAPTCHA is mandatory.

Location:ZIP Code is mandatory

Filter:At least one option is mandatory

TURALIO REMS-Certified Prescriber

Sarcoma Treatment Center

Request a Rep

TURALIO^® (pexidartinib) is available to prescribe! Complete the form below to speak with a sales representative about TURALIO.

*Required information.

First Name *

Please enter your first name. Please enter valid characters in first name Please enter valid first name

Please enter your last name. Please enter valid characters in last name Please enter valid last name

Please enter a valid ZIP Code.

Please enter a valid email address.

True

reCAPTCHA is mandatory.

Mechanism of action

Banner of a healthcare professional in a lab coat wearing a stethoscope

Banner of a healthcare professional in a lab coat wearing a stethoscope

Person depicted is not an actual HCP.

TURALIO acts as a CSF-1 regulator to target the tumor and interrupt cell signaling responsible for tumor growth and inflammation^1,2

Pexidartinib is a small-molecule tyrosine kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF-1R), KIT proto-oncogene receptor
tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation

Overexpression of the CSF-1R ligand promotes cell proliferation and accumulation in the synovium

A detailed graphic showing the TURALIO® (pexidartinib) MOA (mechanism of action). Pexidartinib has been shown to affect CSF-1R on both neoplastic and healthy cells.

A detailed graphic showing the TURALIO® (pexidartinib) MOA (mechanism of action). Pexidartinib has been shown to affect CSF-1R on both neoplastic and healthy cells.

Checkmark icon TURALIO is the first FDA-approved targeted therapy for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery^1,3

Learn about the dosage regimen for TURALIO
DOSAGE

Interested in TURALIO?

Get more information and resources

SIGN UP FOR UPDATES

Sign Up for Updates

TURALIO^® (pexidartinib) is available to prescribe! Complete the form below to contact a sales representative about TURALIO.

*Required information.

Please enter your first name. Please enter valid characters in first name Please enter valid first name

Please enter your last name. Please enter valid characters in last name Please enter valid last name

Please enter a valid email address. Please enter a valid email address.

True

reCAPTCHA is mandatory.

Yes, I want to receive communications from Daiichi Sankyo, Inc. about TURALIO. Please confirm you would like to receive communications.

Yes, I am a healthcare professional. Please confirm you are a healthcare professional.

References: 1. TURALIO [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2025. 2. Tap WD et al. N Engl J Med. 2015;373(5):428-37. 3. FDA approves pexidartinib for tenosynovial giant cell tumor. U.S. Food & Drug Administration; August 8, 2019. Accessed January 3, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pexidartinib-tenosynovial-giant-cell-tumor

Indication and Important Safety Information

Collapse

Expand

IMPORTANT SAFETY INFORMATION

WARNING: HEPATOTOXICITY

TURALIO can cause serious and potentially fatal liver injury, including vanishing bile duct syndrome.
Monitor liver tests prior to initiation of TURALIO and at specified intervals during treatment. Withhold and dose reduce or permanently discontinue TURALIO based on severity of hepatotoxicity. Monitoring and prompt cessation of TURALIO may not eliminate the risk of serious and potentially fatal liver injury.
TURALIO is available only through a restricted program called the TURALIO Risk Evaluation and Mitigation Strategy (REMS) Program.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS

Hepatotoxicity

Hepatotoxicity, including liver failure and life-threatening vanishing bile duct syndrome (VBDS), ductopenia, and symptomatic cholestasis (including severe pruritus) can occur in patients treated with TURALIO and can occur despite monitoring and prompt drug cessation.
The mechanism of cholestatic hepatotoxicity is unknown and its occurrence cannot be predicted. It is unknown whether liver injury can also occur in the absence of increased transaminases.
Of the first 609 patients who received TURALIO under the REMS program, 32 (5.3%) developed a liver injury event of concern, defined as any serious liver-related outcome or any liver abnormality that triggers drug discontinuation per the US Prescribing Information. These 32 patients developed liver toxicity within 71 days of the first dose of TURALIO; ten required hospitalization and two developed VBDS. Sixteen of the 32 patients had not fully recovered at the time of the analysis, including 6 patients followed for at least 6 months after discontinuation.
Among 768 patients who received TURALIO in clinical trials, there were two irreversible cases of cholestatic liver injury. One patient with advanced cancer and ongoing liver toxicity died and one patient with a confirmed case of VBDS required a liver transplant.
In ENLIVEN, 3 of 61 (5%) patients who received TURALIO developed signs of serious liver injury, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 × upper limit of normal (ULN) with total bilirubin ≥2 × ULN. In these patients, peak ALT ranged from 6 to 9 × ULN, peak total bilirubin ranged from 2.5 to 15 × ULN, and alkaline phosphatase (ALP) was ≥2 × ULN. ALT, AST, and total bilirubin improved to <2 × ULN in these three patients 1 to 7 months after discontinuing TURALIO.
Avoid TURALIO in patients with preexisting increased serum transaminases, total bilirubin, or direct bilirubin (>ULN); or active liver or biliary tract disease, including increased ALP.
Monitor liver tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of TURALIO, weekly for the first 8 weeks, every 2 weeks for the next month and every 3 months thereafter.
Withhold and dose reduce, or permanently discontinue TURALIO based on the severity of the hepatotoxicity. Refer patients to a hepatologist if liver tests do not return to normal. Rechallenge with a reduced dose of TURALIO may result in a recurrence of increased serum transaminases, bilirubin, ALP or other signs of liver injury. Monitor liver tests weekly for the first month after rechallenge.

TURALIO REMS

Requirements include: 1) prescribers must be certified by enrolling and completing training, 2) patients must complete and sign an enrollment form for inclusion in a patient registry, and 3) pharmacies must be certified and must dispense only to patients who are authorized (enrolled in the REMS patient registry).
Further information is available at www.TURALIOREMS.com or 1-833-887-2546.

Embryo-Fetal Toxicity

TURALIO may cause fetal harm when administered to a pregnant woman. Advise patients of reproductive potential of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to the initiation of TURALIO.
Advise females of reproductive potential to use an effective nonhormonal method of contraception. TURALIO can render hormonal contraceptives ineffective during treatment with TURALIO and for 1 month after the final dose.
Advise males with female partners of reproductive potential to use effective contraception during treatment with TURALIO and for 1 week after the final dose.

Potential Risks Associated with a High-Fat Meal

Taking TURALIO with a high-fat meal increases pexidartinib concentrations, which may increase the incidence and severity of adverse reactions, including hepatotoxicity.
Instruct patients to take TURALIO with a low-fat meal (approximately 11 to 14 grams of total fat) and to avoid taking TURALIO with a high-fat meal (approximately 55 to 65 grams of total fat).

ADVERSE REACTIONS

The most common adverse reactions (>20%) were increased lactate dehydrogenase (92%), increased AST (88%), hair color changes (67%), fatigue (64%), increased ALT (64%), decreased neutrophils (44%), increased cholesterol (44%), increased ALP (39%), decreased lymphocytes (38%), eye edema (30%), decreased hemoglobin (30%), rash (28%), dysgeusia (26%), and decreased phosphate (25%).

DRUG INTERACTIONS

Hepatotoxic products: Avoid coadministration in patients with increased serum transaminases, total bilirubin, or direct bilirubin (>ULN) or active liver or biliary tract disease.
Moderate or strong CYP3A inhibitors and UGT inhibitors: Concomitant use may increase pexidartinib concentrations. Reduce TURALIO dosage if concomitant use cannot be avoided.
Strong CYP3A inducers: Avoid concomitant use due to decreased pexidartinib concentrations.
Acid-reducing agents: Avoid concomitant use of proton pump inhibitors due to decreased pexidartinib concentrations. Use histamine-2 receptor antagonists or antacids if needed.
CYP3A substrates: Avoid concomitant use where minimal concentration changes may lead to serious therapeutic failure (e.g., hormonal contraceptives) due to decreased concentrations of CYP3A substrates.

USE IN SPECIFIC POPULATIONS

Lactation: Advise not to breastfeed and for at least 1 week after the final dose.
Renal impairment: Reduce the dosage for patients with mild to severe renal impairment.
Hepatic impairment: Reduce the dosage for patients with moderate hepatic impairment. TURALIO has not been studied in patients with severe hepatic impairment.

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

Please see Full Prescribing Information, including Boxed WARNING, and Medication Guide.

INDICATION

TURALIO^Ⓡ (pexidartinib) is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.